Featured in CLI 31.10.2022:
Secretoneurin: a potential complementary cardiovascular biomarker
Secretoneurin is a novel prognostic biomarker that may predict mortality in heart failure and the occurrence of ventricular arrhythmias. Clinical Laboratory International (CLI) caught up with Professor Torbjørn Omland (University of Oslo, Oslo, Norway) to find out more about it.
Featured in CLI 01.09.2022:
Secretoneurin: the next biomarker for cardiovascular disease.
Secretoneurin is a small neuropeptide detectable in the blood and is strong predictor for mortality in several patient cohorts with underlying cardiovascular disease. Here CardiNor introduce themselves and their work to develop a secretoneurin test to use as part of a biomarker panel for cardiovascular disease.
Data from the GISSI Heart Failure study where 1273 patients followed for more than 6 years had their Secretoneurin measured, is presented as Moderated ePosters at the ESC Congress in Barcelona August 28th, station 3 at 14:15 by Dr. Helge Røsjø MD, PhD (Akershus University Hospital, Norway): Circulating Secretoneurin concentrations provide independent prognostic information to established risk indices in patients with chronic heart failure.
Dag Christiansen, CardiNor AS, will be present at the ePosters presentation and is available for questions.
In the media
Clinical Laboratory International, 31.10.2022:
Clinical Laboratory International, 01.09.2022:
Invent2.com, 16.02.2021 (New innovative test for heart disease. Article in Norwegian)
Unicard, 17.11.2016: (secretoneurin predicts mortality in patients with acute respiratory failure. Article in Norwegian)
Scientific Nordic, 02.10.2015: